720 results on '"Hellmich, Bernhard"'
Search Results
2. Head-to-Head-Studien bei Kollagenosen und Vaskulitiden
3. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.
4. Recommendations for defining giant cell arteritis fast-track clinics. English version
5. Patient-reported-Outcomes bei Vaskulitispatienten in Deutschland – Daten aus dem KOBRA-Qualitätsprojekt
6. Labordiagnostik bei Vaskulitiden jenseits von antineutrophilen zytoplasmatischen Autoantikörpern
7. Management der ANCA-assoziierten Vaskulitiden
8. Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors
9. Interstitielle Lungenerkrankungen: Klassifikation, Differenzialdiagnostik und therapeutische Ansätze bei einer heterogenen Gruppe chronischer Lungenerkrankungen
10. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
11. Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis
12. Pulmonale Manifestationen von Vaskulitiden
13. Öffentlichkeitskampagne „rheuma2025“ des Bündnisses für Rheumatologie
14. Diagnostik und Therapie der Riesenzellarteriitis
15. Eosinophile Granulomatose mit Polyangiitis: Update zu Klassifikation und Management
16. Therapie-Update der ANCA-assoziierten Vaskulitiden: Granulomatose mit Polyangiitis und Mikroskopische Polyangiitis
17. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature
18. Biologika bei Kollagenosen und Vaskulitiden
19. Nachrichten des Verbandes Rheumatologischer Akutkliniken e. V.
20. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 195 GCA patients
21. Response to: Correspondence on ‘EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update’ by Hellmichet al
22. Kleine Gefäße, großer Fortschritt
23. Glukokortikoide in der Therapie der Riesenzellarteriitis: Wie viel und wie lange und womit einsparen?
24. Usefulness of vasculitis biomarkers in the era of the personalized medicine
25. Patient perspectives on the burden of eosinophilic granulomatosis with polyangiitis
26. Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis
27. Management of ANCA-associated vasculitides
28. The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis
29. Epidemiology of ANCA-associated vasculitis: does ancestry play a role?
30. Mepolizumab Has Clinical Benefits Including OCS Sparing Irrespective of Baseline EGPA Characteristics
31. The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 266 AAV-patients
32. Patient-reported-Outcomes bei Vaskulitispatienten in Deutschland – Daten aus dem KOBRA-Qualitätsprojekt
33. MEPOLIZUMAB REDUCED STEROID BURDEN FOR PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS WITH AND WITHOUT A VASCULITIC PHENOTYPE
34. Anti-neutrophil cytoplasm antibodies (ANCA): Recent methodological advances—Lead to new consensus recommendations for ANCA detection
35. GCA management guidelines — vive la différence?
36. Cluster Analysis to Explore Clinical Subphenotypes of Eosinophilic Granulomatosis With Polyangiitis
37. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
38. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
39. Pulmonale Manifestationen von Vaskulitiden
40. Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics.
41. EULAR recommendations for the management of ANCA- associated vasculitis: 2022 update.
42. Association of the AAV-PRO questionnaire with established outcome measures in AAV.
43. Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
44. Interstitial lung diseases
45. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
46. Association of the ANCA-associated vasculitis (AAV) patient-reported outcome (AAV-PRO) questionnaire with established outcome measures in AAV
47. Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis.
48. Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
49. Epidemiology of ANCA-associated vasculitis: does ancestry play a role?
50. Großgefäßvaskulitiden
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.